Pharmacogenomics of sulfonylureas in type 2 diabetes mellitus; a systematic review

Leyla Karkhaneh; Ozra Tabatabaei-Malazy; Fatemeh Bandarian; Shahrzad Mohseni; Bagher Larijani

doi:10.1007/s40200-021-00908-x

Pharmacogenomics of sulfonylureas in type 2 diabetes mellitus; a systematic review

J Diabetes Metab Disord. 2021 Dec 1;21(1):863-879. doi: 10.1007/s40200-021-00908-x. eCollection 2022 Jun.

Authors

Leyla Karkhaneh^{1

2}, Ozra Tabatabaei-Malazy³, Fatemeh Bandarian⁴, Shahrzad Mohseni⁵, Bagher Larijani⁵

Affiliations

¹ Personalized Medicine Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran.
² Physiology Department, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran.
³ Non-Communicable Diseases Research Center, Endocrinology and Metabolism Population Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran.
⁴ Diabetes Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, 5th Flat, Diabetes Clinic, Cross Heyat Ave., Shahrivar Ave., North Kargar St., Tehran, Iran.
⁵ Endocrinology and Metabolism Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran.

Abstract

Purpose: Genetic factors have a role in response to a target medication (personalized medicine). This study aimed to review available evidence about the relationship between gene variants and therapeutic response to sulfonylureas in type 2 diabetes, systematically.

Methods: An extensive search was done in Scopus, PubMed, and Web of Science with specific search strategy in the field from the beginning until the 1^st of Jan. 2021. After sending records to endnote software and removing duplicate records remained documents were screened by title and abstract. Full texts of remained documents were assessed after removing un-related records. Required data was extracted from remained documents and records were categorized according to gene/SNP studied.

Results: Finally, 26 studies with 9170 T2DM patients with a mean age of 59.47 ± 6.67 (49.7-75.2 years) remained. The most contribution was from China, Slovakia and Greece, respectively and the most genes studied were CYP2C9, KCNJ11, and both KCNQ1 and ABCC8 with 10, 7, and 4 articles, respectively. Also, rs1799853 and rs1057910 (each with seven studies), rs5219 with six studies and CYP2C9*1(with four articles), respectively were the most common variants investigated. Studies about each gene obtained different positive or negative results and were not consistent.

Conclusion: Considering heterogeneity between SFUs pharmacogenomic studies regarding the method, sample size, population, gene/variant studied, and outcome and findings, these studies are not conclusive and need further studies.

Keywords: Diabetes; Personalized medicine; Pharmacogenomics; Polymorphism; Sulfonylurea; Variant.

Publication types

Review